Role and impact of carbapenem in nosocomial infections

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 1, 2011, Pages 45-53

  Goulenok, Tiphaine M ^a   Majed, Kamel ^b   Monchi, Mehran ^b  

^a BEAUJON HOSPITAL   (France)

^b Department of Intensive Care Medicine   (France)

Author keywords

Antimicrobial resistance; Carbapenem; Nosocomial infection

Indexed keywords

CARBAPENEM DERIVATIVE; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DIFFUSION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG URINE LEVEL; DRUG USE; HOSPITAL INFECTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS INFECTION; DOSAGE FORMS; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PATENTS AS TOPIC;

EID: 79551623206     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111794407886     Document Type: Article

References (77)

1. Falagas ME, Kopterides P. Risk factors for the isolation of multidrug- resistant Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review of the literature. J Hosp Infect 2006; 64(1): 7-15.
2. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al. Imipenem resistance in Pseudomonas aeruginosa: Emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010; 31(1): 47-53.
3. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52(4): 538-42.
4. Koga T, Abe T, Inoue H, Takenouchi T, Kitayama A, Yoshida T, et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother 2005; 49(8): 3239-50.
5. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. Potent in vitro activity of tomopenem (CS-023) against methicillinresistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52(8): 2849-54.
6. Theuretzbacher U. Future antibiotics scenarios: Is the tide starting to turn? Int J Antimicrob Agents 2009; 34(1): 15-20.
7. Tseng, W.-H., Sy-L., Yu, C.-Y. Crystalline carbapenem coumpound and produced method thereof. US20090216010 (2009).
8. Tseng, W.-H., Su,Y.-L., Yu, C.-Y. Crystalline carbapenem compound and produced method thereof. EP2098525 (2009).
9. Brands, K.C.R., Crocker, L., Ward, M., Mahajan, A., Wenslow, R., Williams, J., Sidler, D., Orella, C., Fisher, E., Jobson, R. Crystalline forms of carbapenem antibiotics and method preparation. USRE40794 (2009).
10. Kowalik, E. Carbapenem antibacterials with gram-negative activity processes for their preparation. EP2127650 (2009).
11. George, V.V.B., Prasad, M., Kumar, N., Arora, V. Process for preparing a carbapenem antibiotic composition. WO2009150630 (2009).
12. Huang, Z., Sun, L. Sulfonyl-substituted carbapenem compounds EP2186814 (2010).
13. Dong Y, Huang, Z. Novel carbapenem derivatives. EP2177522 (2010).
14. Rainone, M.P.T., Baird, D., Hantke, R., Phillips, E., Presley, T. Resonance energy transfer based detection of nosocomial infection. WO2009074891 (2009).
15. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: Clinical implications. Clin Pharmacokinet 2000; 39(3): 185-201.
16. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007; 67(7): 1027-52.
17. Hurst M, Lamb HM. Meropenem: A review of its use in patients in intensive care. Drugs 2000; 59(3): 653-80.
18. Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem Pharmacol 2006; 71(7): 1085-95.
19. Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 2006; 32(12): 2059-62.
20. Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 2007; 60(6): 1395-7.
21. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians. J Antimicrob Chemother 2004; 53(Suppl 2): ii23-8.
22. Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy 2004; 24(1): 8-15.
23. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40(2): 219-23.
24. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenemcilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51(9): 3304-10.
25. Bryskier A. Anti-MRSA agents: Under investigation, in the exploratory phase and clinically available. Expert Rev Anti Infect Ther 2005; 3(4): 505-53.
26. Zhanel GG, Johanson, C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban, et al. Ertapenem: Review of a new carbapenem. Expert Rev Anti Infect Ther 2005; 3(1): 23-39.
27. Suarez CJ, Lolans K, Villegas MV, Quinn JP. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections. Expert Rev Anti Infect Ther 2005; 3(6): 915-22.
28. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004 148(8): 3086-92.
29. Villegas MV, Karen L, Adriana C, Juan NK, Jaime AL, John PQ, et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007; 51(4): 1553-5.
30. Nakano V, Padilla G, do Valle Marques M, Avila-Campos MJ. Plasmid-related beta-lactamase production in Bacteroides fragilis strains. Res Microbiol 2004; 155(10): 843-6.
31. Livingstone D, Gill MJ, Wise R. Mechanisms of resistance to the carbapenems. J Antimicrob Chemother 1995; 35(1): 1-5.
32. Cattoir V, Daurel C. Update on antimicrobial chemotherapy. Med Mal Infect 2010; 40(3): 135-54.
33. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003; 21(1): 58-62.
34. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50(1): 73-101.
35. Thomson KS, Moland ES. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillinresistant Staphylococci and Pseudomonas aeruginosa. J Antimicrob Chemother 2004; 54(2): 557-62.
36. Kalyanasundaram, K. Synergistic combinations of aztreonam with the carbapenems meropenem and ertapenem. WO2010064261 (2010).
37. Turner PJ. Mystic Europe 2007: Activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009; 63(2): 217-22.
38. Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: A clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group. J Antimicrob Chemother 1993; 31(6): 927-37.
39. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008; 9(4): 561-75.
40. Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem lower respiratory infection group. Crit Care Med 1997; 25(10): 1663-70.
41. Rea-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: A randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24(7): 2113-26.
42. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36(4):1089-96.
43. Barie PS, Vogel SB, Dellinger EP, Rotstein OD, Solomkin JS, Yang JY, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997; 132(12): 1294-302.
44. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30(5): 868-83.
45. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237(2): 235-45.
46. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009; 53(9): 3782-92.
47. Lee CC, Nan-Yao L, Jing-Jou Y, Hsin-Chun L, Po-Lin C, Chia-Ming C, et al. Bacteremia due to extended-spectrum {beta}- lactamase-producing Enterobacter cloacae: Role of carbapenem therapy. Antimicrob Agents Chemother 2010; 54(9): 3551-6.
48. Fish DN. Meropenem in the treatment of complicated skin and soft tissue infections. Ther Clin Risk Manage 2006; 2(4): 401-15.
49. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128(4): 2336-46.
50. Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: A randomized, double-blind trial. J Clin Oncol 2000; 18(21): 3690-8.
51. Trouillet JL, Jean C, Albert V, Marie-Laure J-G, Danièle C, Marie-Christine D, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157(2): 531-9.
52. Turner PJ. Meropenem activity against European isolates: Report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60(2): 185-92.
53. Cornaglia G, Garau J, Livermore DM. Living with ESBLs. Introduction. Clin Microbiol Infect 2008; 14(Suppl 1): 1-2.
54. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008; 14(Suppl 6): 2-8.
55. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244(5): 379-86.
56. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICUAcquired Pneumonia Study Group. Intensive Care Med 1996; 22(5): 387-94.
57. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115(2): 462-74.
58. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31(12): 2742-51.
59. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50(4): 1257-62.
60. Kwon KT, Oh WS, Jae-Hoon S, Hyun-Ha C, Sook-In J, Shin-Woo K, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59(3): 525-30.
61. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14(11): 1722-30.
62. Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46(9): 2920-5.
63. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43(6): 1379-82.
64. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: Role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38(5): 670-7.
65. Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005; 49(9): 3663-7.
66. Lee SO, Nam JK, Sang-Ho C, Tae HK, Jin-Won C, Jun-Hee W, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: A case-control study. Antimicrob Agents Chemother 2004; 48(1): 224-8.
67. Peterson LR. Squeezing the antibiotic balloon: The impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 2005; 11 (Suppl 5): 4-16.
68. Slama TG. Clinical review: Balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. Crit Care 2008; 12(5): 233.
69. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(Suppl 2): S43-8.
70. Lujan M, Gallego ZM, Rello J. Healthcare-associated infections. A useful concept? Curr Opin Crit Care 2009; 15(5): 419-24.
71. Masterton RG. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 2009; 33(2): 105-110.
72. Kollef MH. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 2001; 29(4 Suppl): N135-42.
73. Gruson D, Hilbert G, Vargas F, Valentino R, Bui N, Pereyre S, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003; 31(7): 1908-14.
74. Brown EM, Nathwani D. Antibiotic cycling or rotation: A systematic review of the evidence of efficacy. J Antimicrob Chemother 2005; 55(1): 6-9.
75. Goldstein EJ, Citron DM, Peraino V, Elgourt T, Meibohm AR, Lu S. Introduction of ertapenem into a hospital formulary: Effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53(12): 5122-6.
76. dos Santos RP, Jacoby T, Goldani LZ. Antimicrobial stewardship lessons: Do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance? Antimicrob Agents Chemother 2010; 54(7): 3076 author reply 3076-7.
77. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010; 31(5): 485-90.